|
TW201625788A
|
|
Monomerizing method for matrix metalloproteinases 7 (MMP-7) associate
|
|
KR20160113206A
|
|
Anti-transthyretin humanized antibody
|
|
KR20160091913A
|
|
Delivery device for absorbable tissue-reinforcing material
|
|
CA2911592A1
|
|
Hybrid gel comprising particulate decellularized tissue
|
|
WO2014109185A1
|
|
Artificial blood vessel using decellularized blood vessel sheet
|
|
WO2014103608A1
|
|
Vaccine for hpv infection and/or hepatitis b containing hpv/hbs chimeric protein as active ingredient
|
|
WO2014080866A1
|
|
Novel human antibody against il-18
|
|
WO2014077096A1
|
|
Method for preventing infections using combination of vector vaccine and live vaccine
|
|
WO2014065210A1
|
|
Vaccine for preventing porcine edema disease
|
|
JP2014040396A
|
|
Adjuvant composition containing dyslipidemia therapeutic agent
|
|
JP2014018352A
|
|
Trace medicine administration instrument
|
|
JP2014018351A
|
|
Medical agent minute-amount administration instrument
|
|
AU2012203101A1
|
|
Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same
|
|
JP2013220076A
|
|
B5r gene defective recombinant vaccinia virus having built-in hemagglutinin protein gene originated from new type influenza virus
|
|
KR20140012115A
|
|
Adjuvant composition containing citrulline
|
|
CN103096944A
|
|
Sheet preparation for tissue adhesion
|
|
JP2012082165A
|
|
New adjuvant
|
|
JP2011092699A
|
|
Tissue adhesion inhibitor
|
|
EP2462942A1
|
|
FXIa HAVING ANTITUSSIVE EFFECT
|
|
WO2011004847A1
|
|
NOVEL HUMANIZED ANTI-HUMAN α9-INTEGRIN ANTIBODY
|
